Susquehanna Fundamental Investments LLC Has $3.92 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Susquehanna Fundamental Investments LLC grew its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 166.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 201,671 shares of the company’s stock after purchasing an additional 126,052 shares during the period. Susquehanna Fundamental Investments LLC owned about 0.17% of 10x Genomics worth $3,923,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in TXG. Allspring Global Investments Holdings LLC lifted its position in shares of 10x Genomics by 113.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock worth $26,000 after buying an additional 371 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in 10x Genomics by 74.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock worth $37,000 after purchasing an additional 808 shares during the last quarter. Covestor Ltd boosted its position in 10x Genomics by 501.7% during the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock worth $39,000 after purchasing an additional 873 shares during the period. Headlands Technologies LLC bought a new stake in 10x Genomics during the first quarter worth approximately $71,000. Finally, Federated Hermes Inc. acquired a new position in 10x Genomics during the second quarter valued at approximately $136,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TXG. Guggenheim reaffirmed a “neutral” rating on shares of 10x Genomics in a report on Tuesday, June 25th. Morgan Stanley dropped their price objective on 10x Genomics from $50.00 to $46.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Canaccord Genuity Group cut their price objective on 10x Genomics from $50.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, July 23rd. UBS Group dropped their price target on 10x Genomics from $30.00 to $25.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 13th. Finally, Wolfe Research reiterated a “peer perform” rating on shares of 10x Genomics in a report on Thursday, June 27th. One analyst has rated the stock with a sell rating, seven have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, 10x Genomics presently has a consensus rating of “Moderate Buy” and an average target price of $31.60.

Insider Buying and Selling at 10x Genomics

In other news, CEO Serge Saxonov sold 6,749 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $152,054.97. Following the completion of the sale, the chief executive officer now owns 882,467 shares of the company’s stock, valued at $19,881,981.51. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other 10x Genomics news, CFO Justin J. Mcanear sold 2,961 shares of the stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $66,711.33. Following the transaction, the chief financial officer now owns 143,242 shares of the company’s stock, valued at $3,227,242.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Serge Saxonov sold 6,749 shares of 10x Genomics stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $152,054.97. Following the transaction, the chief executive officer now directly owns 882,467 shares in the company, valued at $19,881,981.51. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,061 shares of company stock valued at $316,794. 10.03% of the stock is currently owned by company insiders.

10x Genomics Stock Up 1.7 %

NASDAQ:TXG opened at $22.67 on Monday. The firm has a market capitalization of $2.70 billion, a PE ratio of -10.17 and a beta of 1.85. 10x Genomics, Inc. has a 12-month low of $15.28 and a 12-month high of $57.90. The firm has a 50-day moving average price of $21.43 and a 200 day moving average price of $24.49.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.15. The business had revenue of $153.10 million during the quarter, compared to analysts’ expectations of $150.90 million. 10x Genomics had a negative return on equity of 28.23% and a negative net margin of 37.90%. On average, research analysts expect that 10x Genomics, Inc. will post -1.32 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.